ALT 005

Drug Profile

ALT 005

Alternative Names: ALT005; Opthadine

Latest Information Update: 10 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Altacor
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ophthalmic infections

Most Recent Events

  • 04 Aug 2015 Altacor has been acquired by Esperante Ventures
  • 03 Aug 2015 Clinical development is ongoing for Ophthalmic infections (Prevention)
  • 31 May 2012 Altacor completes enrolment in a phase III trial in Ophthalmic infections in USA (NCT01531699)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top